Zenas BioPharma (ZBIO) is down -13.0%, or -$5.28 to $35.31.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib
- Zenas BioPharma Reports Q3 2025 Financial Results
- Zenas BioPharma price target raised to $37 from $34 at Morgan Stanley
- Zenas BioPharma’s Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials
- Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating